×
About 121,913 results

Early Short-Course Corticosteroids in Hospitalized Patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314133
Clinical Infectious Diseases : an Official Publication Of... Fadel R, Morrison AR et. al.

May 20th, 2020 - There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The disease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy in patients with moderate to severe COVID-19. We conducted a single pretest, single posttest quasi-experi...

Pros and cons of corticosteroid therapy for COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351052
Respiratory Physiology & Neurobiology; Mattos-Silva P, Felix NS et. al.

Jul 14th, 2020 - In December 2019, an outbreak of severe pneumonia was reported in Wuhan, China. Later described as COVID-19 (coronavirus disease 2019), this infection caused by a virus from the Coronaviridae family (SARS-CoV-2) has spread globally. Effective therapies for this new disease are urgently needed. In this short communication, we will evaluate the use of corticosteroids a...

Early, Brief Course of Methylprednisolone May Improve COVID-19 Outcomes
https://www.medscape.com/viewarticle/932216

Jun 15th, 2020 - NEW YORK (Reuters Health) - In patients hospitalized for moderate or severe COVID-19, an early, short course of methylprednisolone appears to reduce the risks of death and the need for intensive care and mechanical ventilation, a new quasi-experimental study suggests. These putative benefits were not seen with corticosteroid therapy that b...

Corticosteroid therapy in critically ill patients with COVID-19...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747001
Critical Care (London, England); Li Y, Meng Q et. al.

Dec 20th, 2020 - Corticoid therapy has been recommended in the treatment of critically ill patients with COVID-19, yet its efficacy is currently still under evaluation. We investigated the effect of corticosteroid treatment on 90-day mortality and SARS-CoV-2 RNA clearance in severe patients with COVID-19. 294 critically ill patients with COVID-19 were recr...

Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447292
The American Journal of Case Reports; Urano A, Kasai H et. al.

Aug 17th, 2020 - BACKGROUND The effect of corticosteroids in the management of patients with coronavirus disease 2019 (COVID-19) is unclear. CASE REPORT A 67-year-old man who tested positive for COVID-19 by reverse-transcription PCR (RT-PCR) analysis was admitted to our hospital. On admission, he had no dyspnea and his oxygen saturation (SpO₂) level was normal. Chest im...

Corticosteroid treatment in severe COVID-19 patients with acute re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685724
The Journal of Clinical Investigation; Liu J, Zhang S et. al.

Nov 4th, 2020 - BACKGROUNDCorticosteroids are widely used in patients with COVID 19, although their benefit-to-risk ratio remains controversial.METHODSPatients with severe COVID-19-related acute respiratory distress syndrome (ARDS) were included from December 29, 2019 to March 16, 2020 in 5 tertiary Chinese hospitals. Cox proportional hazards and competing risks analys...

Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864133
Internal and Emergency Medicine; Bahl A, Johnson S et. al.

Feb 7th, 2021 - The optimal timing of initiating corticosteroid treatment in hospitalized patients is unknown. We aimed to assess the relationship between timing of initial corticosteroid treatment and in-hospital mortality in COVID-19 patients. In this observational study through medical record analysis, we quantified the mortality benefit of corticosteroids in two equally m...

Can steroids reverse the severe COVID-19 induced "cytokine storm"?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307112
Journal of Medical Virology References; Kolilekas L, Loverdos K et. al.

Jun 13th, 2020 - Severe coronavirus disease (COVID-19) is characterized by an excessive proinflammatory cytokine storm, resulting in acute lung injury and development of acute respiratory distress syndrome (ARDS). The role of corticosteroids is controversial in severe COVID-19 pneumonia and associated hyper-inflammatory syndrome. We reported a case series of six consecutive

Corticosteroid use in COVID-19 patients: a systematic review and m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735177
Critical Care (London, England); van Paassen J, Vos JS et. al.

Dec 16th, 2020 - In the current SARS-CoV-2 pandemic, there has been worldwide debate on the use of corticosteroids in COVID-19. In the recent RECOVERY trial, evaluating the effect of dexamethasone, a reduced 28-day mortality in patients requiring oxygen therapy or mechanical ventilation was shown. Their results have led to considering amendments in guidelines or actually already recommendin...

Early, Brief Course of Methylprednisolone May Improve COVID-19 Outcomes
https://emedicine.medscape.com/viewarticle/932216

NEW YORK (Reuters Health) - In patients hospitalized for moderate or severe COVID-19, an early, short course of methylprednisolone appears to reduce the risks of death and the need for intensive care and mechanical ventilation, a new quasi-experimental study suggests. These putative benefits were not seen with corticosteroid therapy that b...

Potential benefits of precise corticosteroid therapy for critical COVI...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600764
Respiratory Physiology & Neurobiology; Chen Q, Yang Q et. al.

Nov 22nd, 2021 - This study was aimed to explore the precise dose of corticosteroid therapy in critical COVID-19. A total of forty-five critical COVID-19 patients were enrolled. The process of critical COVID-19 was divided into alveolitis and fibrosis stages. Most nonsurvivors died in fibrosis phase. Nonsurvivors had more dyspnea symptoms, fewer days of ho...

Adjuvant corticosteroid therapy for critically ill patients with COVID-19
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02964-w

A substantial portion of patients with coronavirus disease (COVID-19) developed rapidly progressive pneumonia leading to acute respiratory distress syndrome (ARDS) and multiple organ dysfunctions, conditions associated with high mortality [1]. Adjuvant corticosteroid therapy of such patients is common in clinical practice, but evidence is scarce regarding the efficac...

Fulminant necrotising amoebic colitis after corticosteroid therapy for se...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552158
BMJ Case Reports; Saini R, Bhagat VK et. al.

Oct 29th, 2021 - Acute fulminant necrotising colitis is an uncommon presentation of amoebiasis, which can be precipitated after corticosteroid therapy. Clinicians treating patients with COVID-19 with corticosteroid therapy should be familiar with this condition to avoid delay in diagnosis. The disease is associated with high mortality, and prompt diagnosis and managemen...

Prolonged corticosteroid therapy and cytomegalovirus infection in patient...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661974
Journal of Medical Virology; Yamamoto Y, Shiroyama T et. al.

Oct 29th, 2021 - Systemic corticosteroid therapy is frequently used to treat coronavirus disease 2019 (COVID-19). However, its maximum duration without secondary infections remains unclear. We aimed to evaluate the utility of monitoring cytomegalovirus (CMV) infection in patients with COVID-19 and estimate the maximum duration of systemic corticosteroid

Comparative outcomes of combined corticosteroid and remdesivir therapy wi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865672
PloS One; Mandadi S, Pulluru H et. al.

Feb 24th, 2022 - Remdesivir (RDV) reduces time to clinical improvement in hospitalized COVID -19 patients requiring supplemental oxygen. Dexamethasone improves survival in those requiring oxygen support. Data is lacking on the efficacy of combination therapy in patients on mechanical ventilation. We analyzed for comparative outcomes between Corticosteroid (CS) therapy with com...

The ten reasons why corticosteroid therapy reduces mortality in severe
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538533
Intensive Care Medicine; Arabi YM, Chrousos GP et. al.

Oct 8th, 2020 - The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|2020|Arabi YM,Chrousos GP,Meduri GU,|administration & dosage,therapeutic use,drug therapy,mortality,drug therapy,mortality,

A Review of the Evidence for Corticosteroids in COVID-19.
https://doi.org/10.1177/0897190021998502
Journal of Pharmacy Practice; Johns M, George S et. al.

Mar 16th, 2021 - To review available evidence on corticosteroids in acute respiratory distress syndrome (ARDS), Coronavirus Disease 2019 (COVID-19), and other viral pneumonias. A literature search of MEDLINE, PubMed and clinicaltrials.gov was performed to identify studies between 1980 to 2020 using the following search terms: corticosteroids, COVID19, seve...

Corticosteroid Use in Otolaryngology: Current Considerations During the COVID...
https://doi.org/10.1177/01945998211064275
Otolaryngology--head and Neck Surgery : Official Journal ... Chang CWD, McCoul ED et. al.

Dec 8th, 2021 - To offer pragmatic, evidence-informed advice on administering corticosteroids in otolaryngology during the coronavirus disease 2019 (COVID-19) pandemic, considering therapeutic efficacy, potential adverse effects, susceptibility to COVID-19, and potential effects on efficacy of vaccination against SARS-CoV-2, which causes COVID-19. PubMed, Cochrane Library, EMBASE, CINAHL, and guideline databas...

COVID-19 therapy: Better in combination than alone
https://www.eurekalert.org/news-releases/949734

Apr 13th, 2022 - A joint press release by Charité, the MDC and FU Berlin SARS-CoV-2 infections continue to result in hospitalizations. According to estimates by the Robert Koch Institute, the current COVID-19 hospitalization rate is approximately six to seven per 100,000 of the resident population. Hospitalized COVID-19 patients now have access to a range of drugs which can reduce th...

IgA nephropathy relapse following COVID-19 vaccination treated with co...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988530
BMC Nephrology; Watanabe S, Zheng S et. al.

Apr 9th, 2022 - The flare of immune-mediated disease following coronavirus disease of 2019 (COVID-19) vaccination is a rare adverse event following immunization. De novo, as well as relapsing IgA nephropathy (IgAN) cases, have been reported following either mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccination. To our knowledge, the majority of IgAN relapses did not result in sever...